Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 4/2016

01-04-2016 | Diabetes and Pregnancy (CJ Homko, Section Editor)

Impact of Systemic Inflammation on the Progression of Gestational Diabetes Mellitus

Authors: Tove Lekva, Errol R. Norwitz, Pål Aukrust, Thor Ueland

Published in: Current Diabetes Reports | Issue 4/2016

Login to get access

Abstract

With increasing rates of obesity and new diagnostic criteria for gestational diabetes mellitus (GDM), the overall prevalence of GDM is increasing worldwide. Women with GDM have an increased risk of maternal and fetal complications during pregnancy as well as long-term risks including higher prevalence of type 2 diabetes mellitus and cardiovascular disease. In recent years, the role of immune activation and inflammation in the pathogenesis of GDM has gained increasing attention. This monograph explores the current state of the literature as regards the expression of markers of inflammation in the maternal circulation, placenta, and adipose tissue of women with GDM.
Literature
1.
2.
3.
Retnakaran R, Shen S, Hanley AJ, et al. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring). 2008;16:1901–7.CrossRef
4.
American Diabetes Association. (12) Management of diabetes in pregnancy. Diabetes Care. 2015;38(Suppl):S77–9.CrossRef
5.
Cundy T, Ackermann E, Ryan EA. Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. BMJ. 2014;348:g1567.CrossRefPubMed
6.
Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.CrossRefPubMed
7.
Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25:1862–8.CrossRefPubMed
8.
Tam WH, Ma RC, Yang X, et al. Glucose intolerance and cardiometabolic risk in adolescents exposed to maternal gestational diabetes: a 15-year follow-up study. Diabetes Care. 2010;33:1382–4.CrossRefPubMedPubMedCentral
9.
Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008;31:1668–9.CrossRefPubMedPubMedCentral
10.
Lekva T, Bollerslev J, Norwitz ER, et al. Aortic stiffness and cardiovascular risk in women with previous gestational diabetes mellitus. PLoS One. 2015;10:e0136892.CrossRefPubMedPubMedCentral
11.
Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45.CrossRefPubMed
12.
Mor G, Cardenas I, Abrahams V, et al. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci. 2011;1221:80–7.CrossRefPubMedPubMedCentral
13.
14.
Abell SK, Court D, Boyle JA, et al. Inflammatory and other biomarkers: role in pathophysiology and prediction of gestational diabetes mellitus. Int J Mol Sci. 2015;16:13442–73.CrossRefPubMedPubMedCentral
15.
Pantham P, Aye IL, Powell TL. Inflammation in maternal obesity and gestational diabetes mellitus. Placenta. 2015;36:709–15.CrossRefPubMed
16.
Makhseed M, Raghupathy R, Azizieh F, et al. Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Hum Reprod. 2001;16:2219–26.CrossRefPubMed
17.
Soeters PB, Grimble RF. The conditional role of inflammation in pregnancy and cancer. Clin Nutr. 2013;32:460–5.CrossRefPubMed
18.
Friis CM, Paasche Roland MC, Godang K, et al. Adiposity-related inflammation: effects of pregnancy. Obesity (Silver Spring). 2013;21:E124–30.CrossRef
19.
Christian LM, Porter K. Longitudinal changes in serum proinflammatory markers across pregnancy and postpartum: effects of maternal body mass index. Cytokine. 2014;70:134–40.CrossRefPubMedPubMedCentral
20.
Salustri A, Garlanda C, Hirsch E, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development. 2004;131:1577–86.CrossRefPubMed
21.
Larsson A, Palm M, Helmersson J, et al. Pentraxin 3 values during normal pregnancy. Inflammation. 2011;34:448–51.CrossRefPubMed
22.
Garlanda C, Maina V, Cotena A, et al. The soluble pattern recognition receptor pentraxin-3 in innate immunity, inflammation and fertility. J Reprod Immunol. 2009;83:128–33.CrossRefPubMed
23.
Burton GJ, Jauniaux E, Charnock-Jones DS. The influence of the intrauterine environment on human placental development. Int J Dev Biol. 2010;54:303–12.CrossRefPubMed
24.
Redman CW, Tannetta DS, Dragovic RA, et al. Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta. 2012;33(Suppl):S48–54.CrossRefPubMed
25.
Naruse K, Innes BA, Bulmer JN, et al. Secretion of cytokines by villous cytotrophoblast and extravillous trophoblast in the first trimester of human pregnancy. J Reprod Immunol. 2010;86:148–50.CrossRefPubMed
26.
Svensson-Arvelund J, Ernerudh J, Buse E, et al. The placenta in toxicology. Part II: systemic and local immune adaptations in pregnancy. Toxicol Pathol. 2014;42:327–38.CrossRefPubMed
27.
28.
29.
Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5:266–71.CrossRefPubMed
30.
Tilburgs T, Roelen DL, van der Mast BJ, et al. Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol. 2008;180:5737–45.CrossRefPubMed
31.
Richardson AC, Carpenter MW. Inflammatory mediators in gestational diabetes mellitus. Obstet Gynecol Clin North Am. 2007;34:213–24.CrossRefPubMed
32.
Pendeloski KP, Mattar R, Torloni MR et al. Immunoregulatory molecules in patients with gestational diabetes mellitus. Endocrine. 2015.
33.
Schlossberger V, Schober L, Rehnitz J, et al. The success of assisted reproduction technologies in relation to composition of the total regulatory T cell (Treg) pool and different Treg subsets. Hum Reprod. 2013;28:3062–73.CrossRefPubMed
34.
Schober L, Radnai D, Spratte J, et al. The role of regulatory T cell (Treg) subsets in gestational diabetes mellitus. Clin Exp Immunol. 2014;177:76–85.CrossRefPubMedPubMedCentral
35.
36.
Xie BG, Jin S, Zhu WJ. Expression of toll-like receptor 4 in maternal monocytes of patients with gestational diabetes mellitus. Exp Ther Med. 2014;7:236–40.PubMedPubMedCentral
37.
Kuzmicki M, Telejko B, Wawrusiewicz-Kurylonek N, et al. The expression of genes involved in NF-kappaB activation in peripheral blood mononuclear cells of patients with gestational diabetes. Eur J Endocrinol. 2013;168:419–27.CrossRefPubMed
38.
Catalano P, DeMouzon SH. Maternal obesity and metabolic risk to the offspring: why lifestyle interventions may have not achieved the desired outcomes. Int J Obes (Lond). 2015;39:642–9.CrossRef
39.
Mohammad MK, Morran M, Slotterbeck B, et al. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol. 2006;18:1101–13.CrossRefPubMed
40.
Mullick AE, Tobias PS, Curtiss LK. Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res. 2006;34:193–209.CrossRefPubMed
41.
Schulthess FT, Paroni F, Sauter NS, et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab. 2009;9:125–39.CrossRefPubMed
42.
Moreli JB, Correa-Silva S, Damasceno DC, et al. Changes in the TNF-alpha/IL-10 ratio in hyperglycemia-associated pregnancies. Diabetes Res Clin Pract. 2015;107:362–9.CrossRefPubMed
43.
Noureldeen AF, Qusti SY, Al-Seeni MN, et al. Maternal leptin, adiponectin, resistin, visfatin and tumor necrosis factor-alpha in normal and gestational diabetes. Indian J Clin Biochem. 2014;29:462–70.CrossRefPubMedPubMedCentral
44.
McLachlan KA, O'Neal D, Jenkins A, et al. Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab Res Rev. 2006;22:131–8.CrossRefPubMed
45.
Kinalski M, Telejko B, Kuzmicki M, et al. Tumor necrosis factor alpha system and plasma adiponectin concentration in women with gestational diabetes. Horm Metab Res. 2005;37:450–4.CrossRefPubMed
46.
Lopez-Tinoco C, Roca M, Fernandez-Deudero A, et al. Cytokine profile, metabolic syndrome and cardiovascular disease risk in women with late-onset gestational diabetes mellitus. Cytokine. 2012;58:14–9.CrossRefPubMed
47.
Ozler S, Oztas E, Uygur D et al. The value of total antioxidant status and serum tumor necrosis factor-alpha levels at 24–28 weeks of gestation in the prediction of optimal treatment protocol in gestational diabetes mellitus. Exp. Clin. Endocrinol. Diabetes. 2015. doi:10.​1055/​s00351554623.
48.
Altinova AE, Toruner F, Bozkurt N, et al. Circulating concentrations of adiponectin and tumor necrosis factor-alpha in gestational diabetes mellitus. Gynecol Endocrinol. 2007;23:161–5.CrossRefPubMed
49.
Ategbo JM, Grissa O, Yessoufou A, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab. 2006;91:4137–43.CrossRefPubMed
50.
Cseh K, Baranyi E, Melczer Z, et al. The pathophysiological influence of leptin and the tumor necrosis factor system on maternal insulin resistance: negative correlation with anthropometric parameters of neonates in gestational diabetes. Gynecol Endocrinol. 2002;16:453–60.CrossRefPubMed
51.
Gao XL, Yang HX, Zhao Y. Variations of tumor necrosis factor-alpha, leptin and adiponectin in mid-trimester of gestational diabetes mellitus. Chin Med J (Engl). 2008;121:701–5.
52.•
Guillemette L, Lacroix M, Battista MC, et al. TNFalpha dynamics during the oral glucose tolerance test vary according to the level of insulin resistance in pregnant women. J Clin Endocrinol Metab. 2014;99:1862–9. This study found that higher insulin resistance is associated with higher levels of circulating TNF at first and second trimesters of pregnancy also after adjustment for age, BMI, triglycerides, and adiponectin.CrossRefPubMed
53.
Kalabay L, Cseh K, Pajor A, et al. Correlation of maternal serum fetuin/alpha2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. Eur J Endocrinol. 2002;147:243–8.CrossRefPubMed
54.
Kirwan JP, Hauguel-de MS, Lepercq J, et al. TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes. 2002;51:2207–13.CrossRefPubMed
55.
Winkler G, Cseh K, Baranyi E, et al. Tumor necrosis factor system in insulin resistance in gestational diabetes. Diabetes Res Clin Pract. 2002;56:93–9.CrossRefPubMed
56.
Gauster M, Hiden U, van Poppel M, et al. Dysregulation of placental endothelial lipase in obese women with gestational diabetes mellitus. Diabetes. 2011;60:2457–64.CrossRefPubMedPubMedCentral
57.
Saucedo R, Zarate A, Basurto L, et al. Relationship between circulating adipokines and insulin resistance during pregnancy and postpartum in women with gestational diabetes. Arch Med Res. 2011;42:318–23.CrossRefPubMed
58.
Nergiz S, Altinkaya OS, Kucuk M, et al. Circulating galanin and IL-6 concentrations in gestational diabetes mellitus. Gynecol Endocrinol. 2014;30:236–40.CrossRefPubMed
59.
Morisset AS, Dube MC, Cote JA, et al. Circulating interleukin-6 concentrations during and after gestational diabetes mellitus. Acta Obstet Gynecol Scand. 2011;90:524–30.CrossRefPubMed
60.
Kuzmicki M, Telejko B, Szamatowicz J, et al. High resistin and interleukin-6 levels are associated with gestational diabetes mellitus. Gynecol Endocrinol. 2009;25:258–63.CrossRefPubMed
61.
Hassiakos D, Eleftheriades M, Papastefanou I et al. Increased maternal serum interleukin-6 concentrations at 11 to 14 weeks of gestation in low risk pregnancies complicated with gestational diabetes mellitus: development of a prediction model. Horm. Metab Res. 2015;48:35–41.
62.
Kuzmicki M, Telejko B, Zonenberg A, et al. Circulating pro- and anti-inflammatory cytokines in Polish women with gestational diabetes. Horm Metab Res. 2008;40:556–60.CrossRefPubMed
63.
Maged AM, Moety GA, Mostafa WA, et al. Comparative study between different biomarkers for early prediction of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2014;27:1108–12.CrossRefPubMed
64.
Ozgu-Erdinc AS, Yilmaz S, Yeral MI et al. Prediction of gestational diabetes mellitus in the first trimester: comparison of C-reactive protein, fasting plasma glucose, insulin and insulin sensitivity indices. J. Matern. Fetal Neonatal Med. 2014; 1–6.
65.
Wolf M, Sandler L, Hsu K, et al. First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care. 2003;26:819–24.CrossRefPubMed
66.
Salmi AA, Zaki NM, Zakaria R, et al. Arterial stiffness, inflammatory and pro-atherogenic markers in gestational diabetes mellitus. Vasa. 2012;41:96–104.CrossRefPubMed
67.
Vitoratos N, Valsamakis G, Mastorakos G, et al. Pre- and early post-partum adiponectin and interleukin-1beta levels in women with and without gestational diabetes. Hormones (Athens). 2008;7:230–6.CrossRef
68.
Xu J, Zhao YH, Chen YP, et al. Maternal circulating concentrations of tumor necrosis factor-alpha, leptin, and adiponectin in gestational diabetes mellitus: a systematic review and meta-analysis. Scientific World J. 2014;2014:926932.
69.
Qiu C, Sorensen TK, Luthy DA, et al. A prospective study of maternal serum C-reactive protein (CRP) concentrations and risk of gestational diabetes mellitus. Paediatr Perinat Epidemiol. 2004;18:377–84.CrossRefPubMed
70.
Abdel Gader AG, Khashoggi TY, Habib F, et al. Haemostatic and cytokine changes in gestational diabetes mellitus. Gynecol Endocrinol. 2011;27:356–60.CrossRefPubMed
71.
Georgiou HM, Lappas M, Georgiou GM, et al. Screening for biomarkers predictive of gestational diabetes mellitus. Acta Diabetol. 2008;45:157–65.CrossRefPubMed
72.
Lapolla A, Dalfra MG, Sanzari M, et al. Lymphocyte subsets and cytokines in women with gestational diabetes mellitus and their newborn. Cytokine. 2005;31:280–7.CrossRefPubMed
73.
Khan NA, Yessoufou A, Kim M, et al. N-3 fatty acids modulate Th1 and Th2 dichotomy in diabetic pregnancy and macrosomia. J Autoimmun. 2006;26:268–77.CrossRefPubMed
74.
Yessoufou A, Hichami A, Besnard P, et al. Peroxisome proliferator-activated receptor alpha deficiency increases the risk of maternal abortion and neonatal mortality in murine pregnancy with or without diabetes mellitus: modulation of T cell differentiation. Endocrinology. 2006;147:4410–8.CrossRefPubMed
75.
Montazeri S, Nalliah S, Radhakrishnan AK. Is there a genetic variation association in the IL-10 and TNF alpha promoter gene with gestational diabetes mellitus? Hereditas. 2010;147:94–102.CrossRefPubMed
76.
Telejko B, Kuzmicki M, Zonenberg A, et al. Circulating monocyte chemoattractant protein-1 in women with gestational diabetes. Folia Histochem Cytobiol. 2007;45 Suppl 1:S153–6.PubMed
77.
Kim SY, Sy V, Araki T, et al. Total adiponectin, but not inflammatory markers C-reactive protein, tumor necrosis factor-alpha, interluekin-6 and monocyte chemoattractant protein-1, correlates with increasing glucose intolerance in pregnant Chinese-Americans. J Diabetes. 2014;6:360–8.CrossRefPubMedPubMedCentral
78.
Klein K, Satler M, Elhenicky M, et al. Circulating levels of MCP-1 are increased in women with gestational diabetes. Prenat Diagn. 2008;28:845–51.CrossRefPubMed
79.
Todoric J, Handisurya A, Knapp B, et al. Relationship of pentraxin 3 with insulin sensitivity in gestational diabetes. Eur J Clin Invest. 2013;43:341–9.CrossRefPubMed
80.
Yildirim M, Simavli SA, Uysal DA et al. Is there any relationship between plasma pentraxin 3 levels and gestational diabetes mellitus? Gynecol. Obstet. Invest. 2015;80:223–7.
81.
Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35–40.CrossRefPubMed
82.
Salio M, Chimenti S, De AN, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008;117:1055–64.CrossRefPubMed
83.
Osorio-Conles O, Guitart M, Chacon MR, et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab. 2011;301:E1254–61.CrossRefPubMed
84.
Ogawa T, Kawano Y, Imamura T, et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring). 2010;18:1871–4.CrossRef
85.
Miyaki A, Choi Y, Maeda S. Pentraxin 3 production in the adipose tissue and the skeletal muscle in diabetic-obese mice. Am J Med Sci. 2014;347:228–33.CrossRefPubMed
86.
Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med. 2004;21:103–13.CrossRefPubMed
87.•
Lappas M. Activation of inflammasomes in adipose tissue of women with gestational diabetes. Mol Cell Endocrinol. 2014;382:74–83. This study find an important role for adipose tissue inflammasome activation in the development of insulin resistance associated in pregnancies complicated by GDM.CrossRefPubMed
88.
Black MH, Sacks DA, Xiang AH, et al. The relative contribution of prepregnancy overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes mellitus to fetal overgrowth. Diabetes Care. 2013;36:56–62.CrossRefPubMedPubMedCentral
89.
Lekva T, Bollerslev J, Godang K, et al. β-cell dysfunction in women with previous gestational diabetes is associated with visceral adipose tissue distribution. Eur J Endocrinol. 2015;173:63–70.CrossRefPubMed
90.
Kosus N, Kosus A, Turhan N. Relation between abdominal subcutaneous fat tissue thickness and inflammatory markers during pregnancy. Arch Med Sci. 2014;10:739–45.CrossRefPubMedPubMedCentral
91.
Skvarca A, Tomazic M, Blagus R, et al. Adiponectin/leptin ratio and insulin resistance in pregnancy. J Int Med Res. 2013;41:123–8.CrossRefPubMed
92.
93.
Bao W, Baecker A, Song Y, et al. Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus: a systematic review. Metabolism. 2015;64:756–64.CrossRefPubMed
94.
Hauguel-de MS, Guerre-Millo M. The placenta cytokine network and inflammatory signals. Placenta. 2006;27:794–8.CrossRef
95.
Mrizak I, Grissa O, Henault B, et al. Placental infiltration of inflammatory markers in gestational diabetic women. Gen Physiol Biophys. 2014;33:169–76.CrossRefPubMed
96.•
Aye IL, Lager S, Ramirez VI, et al. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. Biol Reprod. 2014;90:129. This study suggests a link between elevated proinflammatory cytokines in maternal plasma and activation of placental inflammatory pathways.CrossRefPubMedPubMedCentral
97.
Yu J, Zhou Y, Gui J, et al. Assessment of the number and function of macrophages in the placenta of gestational diabetes mellitus patients. J Huazhong Univ Sci Technolog Med Sci. 2013;33:725–9.CrossRefPubMed
98.
Radaelli T, Varastehpour A, Catalano P, et al. Gestational diabetes induces placental genes for chronic stress and inflammatory pathways. Diabetes. 2003;52:2951–8.CrossRefPubMed
Metadata
Title
Impact of Systemic Inflammation on the Progression of Gestational Diabetes Mellitus
Authors
Tove Lekva
Errol R. Norwitz
Pål Aukrust
Thor Ueland
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 4/2016
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-016-0715-9

Other articles of this Issue 4/2016

Current Diabetes Reports 4/2016 Go to the issue

Economics and Policy in Diabetes (ES Huang and A Baig, Section Editors)

The Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential Impacts

Other Forms of Diabetes (JJ Nolan, Section Editor)

Diabetes and Menopause

Hospital Management of Diabetes (GE Umpierrez, Section Editor)

Perioperative Glycemic Management of Patients Undergoing Bariatric Surgery

Diabetes and Pregnancy (CJ Homko, Section Editor)

Bariatric Surgery and the Pregnancy Complicated by Gestational Diabetes

Diabetes and Pregnancy (CJ Homko, Section Editor)

Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus

Microvascular Complications—Nephropathy (AP Maxwell, Section Editor)

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits